Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis

Figures & data

Figure 1 chemical structure of gemifloxacin.

Table 1 Comparison of in vitro activity of gemifloxacin and other quinolones against the typical ABECB organisms. Adapted from Zhanel GG, Fontaine S, Adam H, et al. A review of new fluoroquinolones – focus on their use in respiratory tract infections. Treat Respir Med. 2006;5(6):437–465.³¹ Copyright © 2006, with permission from wolters Kluwer Health pharma Solutions

Antibiotic	Streptococcus pneumoniae		Haemophilus inluenzae		Moraxella catarrhalis
	MIC50	MIC90	MIC50	MIC90	MIC50	MIC90
Gemifloxacin	0.03	0.03	0.004	0.008	0.015	0.015
Levofloxacin	1	1	0.015	0.03	0.06	0.06
Ciprofloxacin	1	2	0.004	0.008	0.03	0.03
Moxifloxacin	0.12	0.12	0.03	0.03	0.06	0.06

Abbreviations: MIC_50/90, drug concentration inibiting 50% and 90% of the number of strains tested in ug/ml.

Table 2 Summary of the clinical and bacterial efficacy of gemifloxacin versus other agents in the treatment Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Int J Antimicrob Agents. 2004;23:533–546. Copyright @ 2004, with permission from elsevier

Study	Comparator	Clinical success in PPP %		Bacteriologic success in PPP %
		Gemifloxacin	Comparator	Gemifloxacin	Comparator
Ball et al^Citation52	None	89.6		91.7
Ball et al^Citation6	Trovafloxacin	91.5	87.6	86.8	82.4
Wilson et al^Citation49	Ceftriaxone/cefuroxime	86.8	81.3	62.5a	60.8a
Wilson et al^Citation51	Clarithromycin	85.4	84.6	86.7	73.1
File et al^Citation51	Amoxicillin/clavulanate	93.6	93.3	90	79.5
Sethi et al^Citation54	Levofloxacin	88.2	85.1

Note:

a – ITT population

Abbreviation: PPP per-protocol population

ZhanelGGFontaineSAdamHA review of new fluoroquinolones – focus on their use in respiratory tract infectionsTreat Respir Med20065643746517154673

 PubMedGoogle Scholar

BallPWilsonRMandellLBrownJHenkelT069 Clinical Study GroupEfficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacinJ Chemother20011328829811450888

 PubMed Web of Science ®Google Scholar

WilsonRA vicious circle hypothesis operating during infective exacerbations of chronic bronchitisMonaldi Arch Chest Dis19944921591648049702

 PubMedGoogle Scholar

WilsonRLanganCBallPGemifloxacin 207 Clinical Study GroupOral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitisRespir Med20039724224912645831

 PubMed Web of Science ®Google Scholar

FileTSchlemmerBGarauJLodeHLynchSYoungCGemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study groupJ Chemother200012431432510949981

 PubMed Web of Science ®Google Scholar

SethiSFogartyCFulambarkerAA randomized double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitisRespir Med200498869770715303633

 PubMed Web of Science ®Google Scholar